金城医药(300233.SZ)：注射用头孢呋辛钠收到药品补充申请批准通知书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for its injectable Cefuroxime Sodium product, indicating a significant advancement in the company's product portfolio and market potential [1] Group 1 - The approved product, injectable Cefuroxime Sodium, is a proprietary drug developed by the company, marketed under the brand name "Lifule" [1] - The drug is produced using technology and raw materials sourced from ACS DOBFAR S.P.A, highlighting a collaboration that may enhance production quality and efficiency [1] - Cefuroxime Sodium is indicated for treating infections caused by bacteria sensitive to the drug, including respiratory, ENT, urinary tract, skin and soft tissue infections, sepsis, meningitis, and bone and joint infections [1] Group 2 - The product is also indicated for the prevention of infections during surgical procedures, such as abdominal, pelvic, orthopedic, cardiac, pulmonary, esophageal, vascular, and total joint replacement surgeries, expanding its application in clinical settings [1]